Artificial Kidney Is Still 'Years' Away - Many Patients Express Disappointment

pexels-photo-5726794-2.jpeg

The Kidney Project’s implantable bioartificial kidney, one that promises to free kidney disease patients from dialysis machines and transplant waiting lists, took another big step toward becoming reality, earning a $650,000 prize from KidneyX for its first-ever demonstration of a functional prototype of its implantable artificial kidney.

KidneyX is a public–private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) founded to “accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases.”

The Kidney Project, a nationwide collaboration led by Shuvo Roy, PhD of UC San Francisco and William Fissell, MD of Vanderbilt University Medical Center (VUMC), combined the two essential parts of its artificial kidney, the hemofilter and the bioreactor, and successfully implanted the smartphone-sized device for preclinical evaluation.

Now after over 20 years of research, the team was awarded KidneyX’s Phase 1 Artificial Kidney Prize. While they have provided no deadline to when the research will be completed, according to their UCSF website, said that it will "provide transformational treatment options beyond current dialysis methods,” in the "coming years."

After nearly a decade of patients donating to the research project directly, many are expressing their disappointment and asking for a transparent itemized list of how the funds are being utilized as well as researchers' salaries. How do you feel about the recent investment and timeframe of continued research?

 

Did this answer your question?

In these extraordinary times, millions rely on KidneyBuzz.com as an independent reporting platform that stands for truth and integrity. You’ve read multiple articles in the last year alone. With no shareholders or billionaire owner, we report on kidney events and breakthroughs with accuracy, free from political and commercial influence. And unlike many others, we’re committed to keeping our kidney-related journalism open for all readers. Every contribution, however big or small, makes a difference. Support us from as little as $1. Thank you.